Cost-effectiveness of everolimus plus reduced tacrolimus in de novo liver-recipients in the Italian setting

References

• Varma V, Mehta N, Kumaran V, Nundy S. Indications and contraindications for liver transplantation. Int J Hepatol 2011;2011:121862
   PubMedGoogle Scholar
• Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675-88
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Skeans MA, Leighton TR, et al. OPTN/SRTR 2011 Annual Data Report: international data. Am J Transplant 2013;13(Suppl 1):199-225
   Google Scholar
• Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999–2008. Am J Transplant 2010;10(4 Pt 2):1003-19
   PubMed Web of Science ®Google Scholar
• McDiarmid SV, Colonna JO, Shaked A, et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplantation 1993;56:847-53
   PubMed Web of Science ®Google Scholar
• Patel HK, Patel A, Abouljoud M, et al. Survival after liver transplantation in patients who develop renal insufficiency. Transplant Proc 2010;42:4167-70
   PubMed Web of Science ®Google Scholar
• Pham PT, Pham PC, Wilkinson AH. Management of renal dysfunction in the liver transplant recipient. Curr Opin Organ Transplant 2009;14:231-9
   PubMed Web of Science ®Google Scholar
• Pillebout E, Nochy D, Hill G, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005;5:1120-9
   PubMed Web of Science ®Google Scholar
• Ganschow R, Pollok JM, Jankofsky M, Junge G. The role of everolimus in liver transplantation. Clin Exp Gastroenterol 2014;7:329-43
   PubMedGoogle Scholar
• Aberg F, Isoniemi H, Hockerstedt K. Long-term results of liver transplantation. Scand J Surg 2011;100:14-21
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Martin P, Messa P. Chronic kidney disease after liver transplantation: Recent evidence. Int J Artif Organs 2010;33:803-11
   PubMed Web of Science ®Google Scholar
• Benten D, Staufer K, Sterneck M. Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner. Nat Clin Pract Gastroenterol Hepatol 2009;6:23-36
   PubMedGoogle Scholar
• Gelson W, Hoare M, Dawwas MF, et al. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation 2011;91:1240-4
   PubMed Web of Science ®Google Scholar
• Moon DB, Lee SG. Liver transplantation. Gut Liver 2009;3:145-65
   PubMed Web of Science ®Google Scholar
• Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-15
   PubMed Web of Science ®Google Scholar
• De SP, Nevens F, De CL, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012;12:3008-20
   PubMed Web of Science ®Google Scholar
• Saliba F, De SP, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013;13:1734-45
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrolimus in de novo liver transplant recipients [Internet]. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2008. https://clinicaltrials.gov/ct2/show/NCT00622869?term=h2304&rank=2. Accessed November 9, 2015
   Google Scholar
• Extension study to evaluate the long-term efficacy and safety of everolimus in liver transplant recipients [Internet]. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2010. https://clinicaltrials.gov/ct2/show?term=h2304&rank=1. Accessed November 9, 2015
   Google Scholar
• Duvoux C, Saliba F, Kaiser G, et al., editors. Efficacy and safety of everolimus with reduced tacrolimus in de novo liver transplant recipients: Long-term results from the H2304E1 study. World Transplant Congress; July 26, 2014; San Francisco; 2014
   Google Scholar
• Novartis. Media Release: Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients. Novartis; 2013 [updated 2013] http://asts.org/docs/default-source/resource/novartis-drug-zortress(r)-is-first-in-over-a-decade-approved-by-fda-to-prevent-organ-rejection-in-adult-liver-transplant-patients.pdf?sfvrsn=0
   Google Scholar
• Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012;26:531-48
   PubMed Web of Science ®Google Scholar
• United Organ Sharing Network [Internet]. https://www.unos.org/data/
   Google Scholar
• Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A. Economic assessment of an anti-HCV screening program in Italy. Value Health 2013;16:965-72
   PubMed Web of Science ®Google Scholar
• Russell RT, Feurer ID, Wisawatapnimit P, Pinson CW. The validity of EQ-5D US preference weights in liver transplant candidates and recipients. Liver Transpl 2009;15:88-95
   PubMed Web of Science ®Google Scholar
• Farmadati Italia 2013. Accessed: 15th June 2013. http://www.farmadati.it/
   Google Scholar
• Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEconomics Italian Research Articles 2009;11:83-93
   Google Scholar
• Camma C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012;56:850-60
   PubMed Web of Science ®Google Scholar
• Rufat P, Fourquet F, Conti F, et al. Costs and outcomes of liver transplantation in adults: a prospective, 1-year, follow-up study. GRETHECO study group. Transplantation 1999;68:76-83
   PubMed Web of Science ®Google Scholar
• Cicchetti ARM, Codella P, Ridolfi A. I costi socio-sanitari dell’insufficienza renale cronica. Farmeconomia e Percorsi Terapeutici 2011;12:21-8
   Google Scholar
• Villa G, Rodriguez-Carmona A, Fernandez-Ortiz L, et al. Cost analysis of the Spanish renal replacement therapy programme. Nephrol Dial Transplant 2011;26:3709-14
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004;22:257-65
   PubMed Web of Science ®Google Scholar
• Das A. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients. Hepatology 2000;31:311-17
   PubMed Web of Science ®Google Scholar
• Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-8
   PubMed Web of Science ®Google Scholar
• McLaughlin K, Manns B, Nickerson P. The routine use of high-resolution immunological screening of recipients of primary deceased donor kidney allografts is cost-effective. Transplantation 2006;81:1278-84
   PubMed Web of Science ®Google Scholar
• Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235-42
   PubMed Web of Science ®Google Scholar